Amgen Inc
AMGN · Healthcare · Biotechnology
Updated 27 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #48 of 500 by Iconic Score · #7 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Amgen Inc (AMGN) is a leading biotechnology company focused on the development and commercialization of innovative therapies for serious illnesses. With a market capitalization of $197.4 billion, Amgen specializes in biologics and biosimilars, targeting areas such as oncology, nephrology, and inflammatory diseases. The company leverages advanced genetic and molecular biology techniques to create groundbreaking treatments, positioning itself as a key player in the healthcare sector. Amgen's robust pipeline and established portfolio of blockbuster drugs, including therapies like Enbrel and Neulasta, underscore its significant role in addressing unmet medical needs. As a pioneer in biotechnology, Amgen not only contributes to advancements in patient care but also plays a vital role in shaping the future of healthcare through innovation and research.
IconicOracleAI™ Brief
Amgen Inc (AMGN) currently holds an Iconic Score of 65, reflecting solid brand visibility with a score of 85/100 from logo analysis. Recent headlines highlight a 10% sales growth, indicating strong market performance, while ongoing developments, such as the Phase III Tezspire data collaboration with AstraZeneca, enhance its visibility in the biotech sector. However, the slight decline in stock price suggests a cautious sentiment among investors as they assess the company's ability to align earnings with its growth trajectory.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.